rss Posted March 21, 2022 Report Share Posted March 21, 2022 J Cosmet Dermatol. 2022 Mar 21. doi: 10.1111/jocd.14692. Online ahead of print. ABSTRACT BACKGROUND: Botulin toxin (BTX) is a potent neurotoxin produced by the bacterium Clostridium botulinum, since its approval by FDA in 2002 for cosmetic purpose has been widely used. Recent studies indicate that it exerts its activity on various type of skin cells and can be used in some dermatological disease. OBJECTIVE: The aim of the study was to demonstrate how to use a peculiar dilution of botulinum toxin type A in the treatment of some dermatological disease like mild-to-moderate acne vulgaris and erythematotelangiectatic rosacea. MATERIAL AND METHODS: 50 patients were enrolled, 35 with mild-to-moderate acne and 15 with erythematotelangiectatic rosacea. Both group of patients were treated with a specific dilution of Onabotulinum toxin A called Microbotox. Patient images were taken before and 4 weeks after the treatment. RESULTS: The authors and patients were extremely satisfied with their treatments. There were no immediate or delayed complication in none of both group of patients. CONCLUSION: Botulinum toxin shows a great promise either in dermatological disease like mild-to-moderate acne vulgaris and erythematotelangiectatic rosacea. Microbotox appears to be a valid, long-lasting, and a standardized approach to treat these kind of two disease. PMID:35312149 | DOI:10.1111/jocd.14692 {url} = URL to article RRDi Members ONLY: Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now